Bob Toia, 77, had a career in drug research, developing clinical trials for new drug entities at Proctor and Gamble. During those years, he…
At the 2024 Clinical Trials on Alzheimer’s Disease (CTAD) conference in Madrid, Spain, scientists and drug development companies gathered to report on recent successes…
Athira Pharma’s experimental Alzheimer’s drug fosgonimeton hit a speedbump on its way toward FDA approval: The treatment failed to show a clinical benefit in…
During the Alzheimer’s Association International Conference in Philadelphia last week, researchers and drug companies presented data on a range of different Alzheimer’s drugs. Amidst…
In a recent survey, Being Patient put a question to readers: “What is the biggest barrier preventing you from seeking a trial?” The most…
In the past year, the FDA approved two landmark new Alzheimer’s drugs: monoclonal antibodies designed to attack the disease’s underlying pathology, as opposed to…
Cassava Sciences’ experimental Alzheimer’s drug simufilam is currently in clinical trials. Meanwhile, the company is experiencing a major shake-up. Its CEO and lead neuroscientist…
It’s been a big year for Alzheimer’s research. Between July 6 of last year and this July 2, two disease-modifying drugs for Alzheimer’s disease received full…
It can be challenging to find information about Alzheimer’s clinical trials, let alone find trial participants’ first-hand accounts of their experiences. People living with…
There are more than 500 active clinical trials for Alzheimer’s and other dementias in the U.S. They are designed to test different interventions, such…
Clinical trials and studies scientific experiments that investigate new treatments, lifestyle interventions, or risk factors for developing a disease like Alzheimer’s or dementia. By…
Update 17 July, 2024, 3:14 p.m. ET: Cassava Sciences CEO and SVP of neuroscience have resigned from the company following news of federal probes….
How does science go from the lab to the news stand? Scientists design experiments to test an idea or hypothesis. Some experiments involve lots…
It’s an exciting time for Alzheimer’s research, according to Madhav Thambisetty, senior investigator at the National Institute on Aging. “We’ve known for years that…
The monoclonal antibody drugs targeting the brain’s amyloid plaques dominated the news cycle in 2023. Eisai and Biogen’s Leqembi was approved by the FDA…